Immuneering Corp Competitors
| IMRX Stock | USD 5.19 -0.15 -2.81% |
Correlation: Immuneering Corp vs Entrada Therapeutics Snapshot
Weak diversification
The correlation between Immuneering Corp and Entrada Therapeutics is 0.54, which Macroaxis classifies as Weak diversification for the selected horizon. In portfolio terms, the overlap shows how much shared movement remains after combining both positions.
The mean reversion effect in Immuneering Corp is stronger when the initial deviation was driven by sentiment rather than fundamentals. Such deviations have sometimes corrected when the initial catalyst fades, though timing remains uncertain. The degree to which Immuneering Corp's exhibits mean reversion depends on how efficiently the market prices new information. Short-term deviations tend to persist and even widen before correcting, making allocation calibration important.
Immuneering Corp Competition Correlation Matrix
Studying peer correlation around Immuneering Corp provides a cleaner read on how much independent price behavior still exists across the competitive set. The business currently sits in the Healthcare sector and the Biotechnology industry. In practical terms, lower correlation may offer better diversification while higher correlation may leave the portfolio more exposed to one shared driver.
Please upgrade your account to get full access to Macroaxis premium features
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Return momentum in Immuneering Corp Stock is more useful when tested against peer-relative fundamentals and risk. Reviewing Immuneering Corp's risk-adjusted indicators gives a clearer view of whether returns are being earned efficiently. These indicators are quantitative in nature and measure volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| FHTX | 2.68 | -0.27 | 0.00 | 0.39 | 0.00 | 5.51 | 21.52 | |||
| PYXS | 3.92 | 0.77 | 0.16 | 0.37 | 3.77 | 11.11 | 24.00 | |||
| NAUT | 4.53 | 0.63 | 0.11 | 0.38 | 5.08 | 10.88 | 39.09 | |||
| ZURA | 3.17 | -0.44 | 0.00 | -0.32 | 0.00 | 6.00 | 17.83 | |||
| HUMA | 6.03 | 0.39 | 0.05 | 0.15 | 7.20 | 10.20 | 49.60 | |||
| ASMB | 2.74 | 0.18 | 0.05 | 0.11 | 3.42 | 6.05 | 17.85 | |||
| ENTA | 2.22 | 0.19 | 0.05 | 0.12 | 3.21 | 4.16 | 20.18 | |||
| ARCT | 2.78 | 0.34 | 0.11 | 0.18 | 2.84 | 6.87 | 17.18 | |||
| TNYA | 5.06 | 0.13 | 0.02 | 0.11 | 5.33 | 8.96 | 49.49 | |||
| TRDA | 3.93 | -0.35 | 0.00 | -0.14 | 0.00 | 7.22 | 13.90 |
Peer Comparison: Net Income
Net income is what remains after all costs — operating expenses, interest, taxes, and preferred dividends — are deducted from Immuneering Corp's total revenue. The relationship between net income growth and revenue growth at Immuneering Corp reveals whether margin expansion is driving earnings or whether top-line growth is being consumed by rising costs and financing charges.Compare Immuneering Corp and related stocks such as Foghorn Therapeutics, Pyxis Oncology, and Nautilus Biotechnology Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FHTX | -26.3 M | -26.3 M | -26.3 M | -26.3 M | -26.3 M | -26.3 M | -26.3 M | -26.3 M | -26.3 M | -51.1 M | -68.8 M | -101.3 M | -108.9 M | -98.4 M | -86.6 M | -74.3 M | -78 M |
| PYXS | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M | -12.8 M | -76 M | -118 M | -73.8 M | -77.3 M | -79.6 M | -83.6 M |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | -9.6 M | -15.6 M | -50.3 M | -57.9 M | -63.7 M | -70.8 M | -59 M | -56.1 M |
| ZURA | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | -25.7 M | -60.4 M | -52.4 M | -99.4 M | -94.4 M |
| HUMA | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -85.4 M | -66.5 M | -26.5 M | -12 M | -110.8 M | -148.7 M | -40.8 M | -42.9 M |
| ASMB | -8.8 M | -34.3 M | -24.8 M | -19.4 M | -23.8 M | -28.5 M | -44.3 M | -42.8 M | -90.8 M | -97.6 M | -62.2 M | -129.9 M | -92.1 M | -61.2 M | -40.2 M | -6.1 M | -6.4 M |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | -36.2 M | -79 M | -121.8 M | -133.8 M | -116 M | -81.9 M | -73.7 M | -70 M |
| ARCT | -3.9 M | -3.9 M | -1.6 M | -10.5 M | -32.8 M | -19.4 M | -24.6 M | -10.9 M | -21.8 M | -26 M | -72.1 M | -203.7 M | 9.3 M | -29.7 M | -80.9 M | -65.8 M | -62.5 M |
| TNYA | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -25.8 M | -38.4 M | -69.7 M | -123.7 M | -124.1 M | -111.1 M | -90.6 M | -95.1 M |
| TRDA | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -4.6 M | -26.5 M | -50.1 M | -87.5 M | -6.7 M | 65.6 M | -143.8 M | -136.6 M |
Immuneering Corp Competitive Analysis
Among Foghorn Therapeutics, Pyxis Oncology, and Nautilus Biotechnology and Immuneering Corp, each company brings a distinct financial profile to the table. Immuneering Corp posts a -43.12% return on equity, reflecting current earnings headwinds. On equity returns, Immuneering Corp earns -43.12% compared to -470.38% at Foghorn Therapeutics. Immuneering Corp dwarfs Pyxis Oncology on market cap at 335.8 M versus 144.6 M. Return on equity favors Nautilus Biotechnology at -33.69%, well ahead of Immuneering Corp at -43.12%.| Better Than Average | Worse Than Peers | View Performance Chart |
Immuneering Corp Competition Peer Performance Charts
How to Analyze Immuneering Corp Against Peers
Immuneering Corp's peer analysis compares Immuneering Corp with related companies to put valuation, quality, and risk metrics in context. This establishes whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Immuneering Corp trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Immuneering Corp leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Dividend growth at Immuneering Corp has outpaced most competitors, suggesting management sees durable cash flow ahead. Customer concentration risk differs across Immuneering Corp's peer group, which affects earnings stability in a downturn. Comparing operational quality across peers can be more informative than reading one company in isolation. For peer comparison, Immuneering Corp has a market cap of 335.78 million.
Immuneering Corp values are built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Where analyst coverage exists, consensus estimates are factored in.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board